Expertise in
5
conditions

Hung-chih S. Yang

1 Chang Te Street, 
TPQ, TW 
Expertise in
5
conditions
1 Chang Te Street, 
TPQ, TW 
OverviewLocationsClinical Research

Overview

Hung-chih Yang practices in Taiwan. Yang is highly rated in 5 conditions, according to our data. Their top areas of expertise are Hepatitis B, Hepatitis, Hepatitis C, Cirrhosis, and Heart Transplant.

Their clinical research consists of co-authoring 151 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

1 Chang Te Street, TPQ 10048, Taiwan
Other Locations
7 Chung Shan South Road, TPQ 10002, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Enrollment Status: Active_not_recruiting
Publish Date: July 05, 2024
Intervention Type: Drug
Study Phase: Not Applicable
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
Enrollment Status: Terminated
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Enrollment Status: Completed
Publish Date: March 11, 2020
Intervention Type: Drug
Study Phase: Phase 4
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Enrollment Status: Completed
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

151 Total Publications

Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
Journal: Hepatology (Baltimore, Md.)
Published: May 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yang's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile